Truist Securities Upgrades Corcept Therapeutics to Buy, Raises Price Target to $38
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Joon Lee has upgraded Corcept Therapeutics (NASDAQ:CORT) from Hold to Buy and raised the price target from $29 to $38.
November 06, 2023 | 1:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Corcept Therapeutics has been upgraded from Hold to Buy by Truist Securities, with a raised price target from $29 to $38.
The upgrade from Hold to Buy indicates a positive outlook for Corcept Therapeutics by Truist Securities. The raised price target from $29 to $38 suggests that the analyst expects the stock to perform well in the short term. This could potentially lead to an increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100